TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02299206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeraVe Baby Diaper Rash Cream
Description: Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desitin Maximum Strength Original Paste
Description: Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
Study: NCT03421262

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IADPSG Criteria
Description: One-step: 2 hr 75 gr OGTT

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NDDG Criteria
Description: Osullivan test + 3 h 100 g OGTT
Study: NCT03426644

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Sleep and Growth Study
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Sleep and Growth Study
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Sleep and Growth Study
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Sleep and Growth Study
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
Study: NCT04717167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Needling
Study: NCT03765177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLIC-1901
Description: Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.
Study: NCT00762528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Copolymer/fluoride toothpaste
Description: Twice daily usage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium monofluorophosphate toothpaste
Description: Twice daily usage
Study: NCT00533780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Healing Touch
Description: A gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy.
Study: NCT03885076

Intervention type: PROCEDURE
Intervention: Blood collection and bone marrow aspirate
Description: Blood and bone marrow samples will be collected for the trial alongside routine tests.
Study: NCT04300842

Intervention type: DEVICE
Intervention: smart bracelet
Description: to measure the stress, fatigue, and activity.

Intervention type: DEVICE
Intervention: smart bracelet
Description: to measure the stress, fatigue, and activity.
Study: NCT02382952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Differential Dissector

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dissection Method
Study: NCT03935594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Injection
Description: 1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.
Study: NCT03006367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1 800 mg
Study: NCT00858650

Intervention type: OTHER
Intervention: Standard of Care
Description: Standard of care may or may not include use of testosterone replacement therapy
Study: NCT03935594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Injection
Description: 1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Injection
Description: 1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Injection
Description: 1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
Study: NCT03760302

Intervention type: OTHER
Intervention: analgesics
Description: analgesics given to a patient treated from HEMS

Intervention type: OTHER
Intervention: hypnotics
Description: hypnotics given to a patient treated from HEMS
Study: NCT02098655

Intervention type: OTHER
Intervention: Stabilometric platform
Description: Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.

Intervention type: OTHER
Intervention: Stabilometric platform
Description: Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
Study: NCT01608139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
Study: NCT04128176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab combined with Omalizumab
Description: Rituximab 1000 mg will be administered by IV infusion 6 months after the patient's initial cycle of rituximab (received in the screening period).Omalizumab (300 mg) will be administered subcutaneously every 2 weeks starting on Day 1 until week 24 (primary endpoint) and again until week 52 (secondary endpoint).
Study: NCT04316923

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG will be performed during each visit in the study group.

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG will be performed during each visit in the study group.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ECG monitoring
Description: 24-hour ECG monitoring will be performed during each visit in the study group.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ECG monitoring
Description: 24-hour ECG monitoring will be performed during each visit in the study group.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardio-pulmonary exercise test (CPET)
Description: CPET will be performed during the first and the last visit in the study group.
Study: NCT01608139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
Study: NCT02967172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study: NCT03792763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1.7 ml Subcutaneous Solution
Description: Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
Study: NCT00372411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Therapy - MIT-MANUS System
Description: The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Comparison Therapy
Description: The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The usual chronic stroke care as delivered at each participating medical center
Study: NCT02266537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05183386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental socket regeneration
Description: after a dental extraction the fresh socket is filled with graft materials and compared with the spontaneous healing (control)
Study: NCT01595789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
Study: NCT02967172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride solution
Study: NCT03394196

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV-2 Genotypic Drug Resistance Testing using DBS
Description: Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV-2 Genotypic Drug Resistance Testing using DBS
Description: Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.
Study: NCT01595789

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
Study: NCT03032458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
Study: NCT04364659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food-Specific Inhibitory Control Training (FoodT App)
Description: FoodTrainer (FoodT) is a simple game that aims to train individuals to 'stop' to certain unhealthy foods. Repeatedly playing this game is hypothesised to help build associations between certain foods (such as chocolate) and stopping, putting the brakes on unhelpful eating behaviour.
Study: NCT00086983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02160249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facility based care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facility based care
Study: NCT03032458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine Gel
Description: Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
Study: NCT03087877

Intervention type: DEVICE
Group type: OTHER
Intervention: Acetaminophen Challenge (G6 CGM)
Description: Evaluation of acetaminophen effect on CGM glucose sensing
Study: NCT04316923

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardio-pulmonary exercise test (CPET)
Description: CPET will be performed during the first and the last visit in the study group.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac biomarkers
Description: Cardiac biomarkers will be assessed during each visit in the study group.
Study: NCT00018200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benztropine
Description: Daily dose 0.125 to 0.5mg
Study: NCT03394196

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV-2 Genotypic Drug Resistance Testing using DBS
Description: Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)
Description: 1. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
Description: 2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)
Description: 3. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
Study: NCT03371459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS MDI
Description: AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil
Description: Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
Study: NCT01265433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S + Montanide + GM-CSF
Description: Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self administered) subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Montanide + GM-CSF
Description: Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self-administered)subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
Study: NCT03466268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gumarontinib Tablets
Description: Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
Study: NCT01326910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Oatmeal
Description: Topical cream applied twice daily (or as needed)

Intervention type: DEVICE
Group type: OTHER
Intervention: Topical Cream
Description: Topical cream applied twice daily (or as needed)
Study: NCT00310063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupressure therapy
Description: Acupressure wristband
Study: NCT04164225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong Exercise
Description: Participants with chronic low back pain will follow the free 5 elements Qigong healing class (estimate of 6 hours) at the Spring Forest Qigong center and then practice the 5 elements healing Qigong at home 3 times a week for 40 minutes with a freely available online video, for 12 weeks. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: P.Volve Exercises
Description: P.Volve exercise focuses on low impact core strengthening, core stabilization, and stretching. The program is similar in delivery as Qigong (i.e., online videos). An introductory class (estimate of 2.5h) will be given by the P.Volve team, the principal investigator, and a physical therapist who has experience with P.Volve exercises. Participants will access online videos for individual home practice in 40min/session, 3x/week for 12 weeks. Participants will receive a P.ball for some exercises, while other exercises are done with no equipment. Tailored videos will be available for those with cLBP. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.
Study: NCT00310063

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: Sham wristband
Study: NCT03822546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional cigarette
Description: Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myblu 25 mg freebase
Description: E-cigarette used for 10 inhalations every 30 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myblu 16 mg nicotine salt
Description: E-cigarette used for 10 inhalations every 30 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myblu 25 mg nicotine salt
Description: E-cigarette used for 10 inhalations every 30 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myblu 40 mg nicotine salt
Description: E-cigarette used for 10 inhalations every 30 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu PRO 48 mg nicotine salt
Description: E-cigarette used for 10 inhalations every 30 seconds
Study: NCT01339104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
Study: NCT02705755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.